Arimoclomol Drug Asset Due Diligence Report 2026

This Arimoclomol Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Arimoclomol can convert its Small molecule drug profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Arimoclomol (query alias: arimoclomol)
Modality / target	Small molecule drug; Not disclosed; Molecular chaperones modulators, Protein biosynthesis stimulants
Highest global status	Approved
Originator	Strategic Partners A/S
Active developers	Zevra Therapeutics, Inc., Zevra Denmark A/S, University College London

The MCP disease footprint includes Niemann-Pick Disease, Type C, Amyotrophic Lateral Sclerosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04049097	Phase 3	Terminated	121	Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score
NCT03836716	Phase 3	Terminated	120	Number of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Open-label Treatment Period
NL-OMON49378	Not Applicable	Completed	32	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial

Phase 2/3; n=50; evaluation: Positive. Reported fields: -; 5DNPCCSS(＞48-month) = 3.2 Point (SD, 4.8)

FDA-Approved Drugs-MIPLYFFA-CLINICAL STUDIES

Phase 3; n=50; evaluation: Positive. Reported fields: R4DNPCCSS(12-month; Mean) = 1.9 Point (SD, 3.4); R4DNPCCSS(12-month; Mean) = -0.2 Point (SD, 1)

An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial

Phase 3; n=121; evaluation: not stated. Reported fields: -; Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score(Mean) = -1.7 score on a scale (Standard Deviation, 2.60); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Arimoclomol addresses Niemann-Pick Disease, Type C, Amyotrophic Lateral Sclerosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-04-27	Ligand snaps up fellow biotech royalty aggregator Xoma for $739M	Approved	US$739.0M stated total
2025-12-29	Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)	Approved	Financial terms not disclosed
2022-05-15	Orphazyme completes sale of substantially all of its assets and business activities to KemPharm	NDA/BLA	US$18.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Arimoclomol compositions for use in treating niemann pick disease type c (NPC)”. The milestone feed surfaced a patent-application signal described as “Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations”. The milestone feed surfaced a patent-application signal described as “Use of arimoclomol in the treatment of niemann pick disease”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO